Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon α plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 10, 2007, Pages 906-909

  Potthoff, Andrej ^a   Deterding, Katja ^a   Trautwein, Christian ^b   Rifai, Kinan ^a   Manns, Michael P ^a   Wedemeyer, Heiner ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Hepatitis B vaccination; Hepatitis B C coinfection; Hepatitis Bs seroconversion; Pegylated interferon and ribavirin

Indexed keywords

CITALOPRAM; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2B; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG MECHANISM; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 34548703582     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282094160     Document Type: Article

References (25)

1. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Ceccheffo A, Alberi A. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74:2442-2448.
2. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, Lobello S. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-2137.
3. Weltman MD, Brotodihardjo A, Crewe EB, Farrell GC, Bilous M, Grierson JM, Liddle C. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Vir Hep 1995; 2:39-45.
4. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024-1029.
5. Raimondo G, Brunetto MR, Pontiso P, Smedile A, Maina AM, Saitta C, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006; 43:100-107.
6. Jardi R, Rodriguez F, Buti M, Cotrina M, Galimany R, Esteben R, Guardia J. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001; 34:404-410.
7. Dai CY, Yu ML, Chuang WL, Lin ZY, Chen SC, Hsieh MY, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2001; 16:636-640.
8. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 2002; 37 (Suppl 13):65-68.
9. Villa E, Grottola A, Trande P, Seium Y, Rebecchi AM, Dugani A, Manenti F. Reactivation of hepatitis B virus infection induced by interferon (IFN) in HBsAg-positive, antiHCV-positive patients. Lancet 1993; 341 (8857):1413.
10. Yalcin K, Degertekin H, Yildiz F, Kilinc N. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with interferon and ribavirin. J Gastroenterol 2003; 38:796-800.
11. Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al. High doses of a-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001; 96:2973-2977.
12. Marrone A, Zampino R, D'Onofrio M, Ricciotti R, Ruggiero G, Utili R. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004; 41:1064-1065.
13. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003; 37:568-576.
14. Hung CH, Lee CM, Lu SN, Wang JH, Tung HD, Chen CH, Changchien CS. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. J Gastroenterol Hepatol 2005; 20:727-732.
15. Chuang WL, Dai CY, Chang WY, Lee LP, Lin ZY, Chen SC, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005; 10:125-133.
16. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
17. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003; 38:543-544.
18. Fleig WE, Krummenerl P, Lesske J, Dienes HP, Zeuzem S, Schmiegel WH, et al. Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents: results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and in cooperation with the hepatitis competence network. Z Gastroenterol 2004; 42:703-704.
19. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kDa)/ribavirin. J Hepatol 2005; 43:425-433.
20. Rautou PE, Asselah T, Saadoun D, Martinot M, Valla D, Marcellin P. Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-a2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. Eur J Gastroenterol Hepatol 2006; 18:1019-1022.
21. Crespo J, Lozano JL, Carte B, de las Heras B, de la Cruz F, Pons-Romero F. Viral replication in patients with concomitant hepatitis B and C virus infections. Eur J Clin Microbiol Infect Dis 1997; 16:445-451.
22. Pontisso P, Gerotto M, Ruvoletto MG, Fattovich G, Chemello L, Tisminetzky S, et al. Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. J Med Virol 1996; 48:157-160.
23. Saitta C, Pontisso P, Brunetto MR, Fargion S, Gaeta GB, Niro GA, et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir Ther 2006; 11:931-934.
24. Bocher WO, Herzog-Hauff S, Herr W, Heermann K, Gerken G, Meyer Zum Buschenfelde KH, et al. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1996; 105:52-58.
25. Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N, et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 2007; 46:635-644